독소루비신 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Doxorubicin Market was valued at USD 1.3 billion in 2023 and is projected to depict a 6.3% CAGR from 2024 to 2032. Doxorubicin, derived from the bacterium Streptomyces Peucetius, is an anthracycline-based chemotherapy drug predominantly used to treat various cancers. It disrupts the DNA of cancer cells, halting their growth and division, and ultimately leading to cell death. The surging global cancer incidence significantly propels the market's expansion. For example, the World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. Such statistics highlight the escalating demand for potent chemotherapy agents like doxorubicin, as the rising cancer burden calls for advanced and widely adopted treatment modalities.

Moreover, innovations in chemotherapy, an emphasis on personalized medicine, and heightened government investments in cancer research further bolster the doxorubicin market's revenue growth. The overall doxorubicin industry is classified based on application, drug formulation, distribution channel, and region. Segmented by drug formulations, the doxorubicin market comprises lyophilized powder and doxorubicin injection. Projections suggest the doxorubicin injection segment will hit USD 1.3 billion by 2032. Doxorubicin effectively targets a myriad of cancers, including but not limited to breast cancer, lymphoma, leukemia, and sarcoma.

Its broad-spectrum efficacy positions it as a pivotal treatment choice. The injectable variant amplifies this versatility, ensuring swift action and systemic treatment, allowing the drug to promptly engage cancer cells throughout the body. Applications of doxorubicin span liver, breast, lung, and kidney cancers, among others. In 2023, the breast cancer segment alone generated USD 301.8 million.

Doxorubicin's adaptability allows its application across all breast cancer stages, from early detection to metastatic phases, thanks to its broad cancer cell targeting. This flexibility not only solidifies its significance in varied clinical scenarios but also explains the breast cancer segment's dominant market share. In the U.S., the doxorubicin market is on track to reach USD 771.7 million by 2032. The rising cancer prevalence in the U.S. significantly fuels the doxorubicin market's growth. Data from the Centers for Disease Control and Prevention (CDC) indicates that in 2020, there were 1,603,844 new cancer diagnoses, with 602,347 resulting in fatalities.Such rising figures underscore the urgent demand for effective therapeutic solutions. Moreover, the U.S. is home to a sophisticated healthcare framework, featuring advanced hospitals and specialized cancer centers, ensuring optimal management of doxorubicin therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Advancements in chemotherapy treatments
    • 3.2.1.3 Growing focus on personalized medicine
    • 3.2.1.4 Growth in government funding for cancer research
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of alternative therapies
    • 3.2.2.2 Side effects associated with the medication
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Formulation, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Lyophilized powder
• 5.3 Doxorubicin injection

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Breast cancer
• 6.3 Liver cancer
• 6.4 Kidney cancer
• 6.5 Sarcoma
• 6.6 Ovarian cancer
• 6.7 Lung cancer
• 6.8 Leukemia
• 6.9 Multiple myeloma
• 6.10 Other types of cancer

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Accord Healthcare
• 9.2 Baxter International Inc.
• 9.3 Cipla Ltd.
• 9.4 Dr. Reddy's Laboratories Limited
• 9.5 Fresenius SE & Co. KGaA
• 9.6 Johnson and Johnson
• 9.7 Hikma Pharmaceuticals PLC
• 9.8 Lupin Limited
• 9.9 Meiji Holdings Co. Ltd.
• 9.10 Novartis AG
• 9.11 Pfizer Inc.
• 9.12 Sun Pharmaceutical Industries Ltd.
• 9.13 Sanofi
• 9.14 Teva Pharmaceutical Industries Ltd.
• 9.15 Viatris Inc.
• 9.16 Zydus Lifesciences Limited